|
| 36689092 | Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. | Breast Cancer Res Treat | 2023 |
| 36316952 | Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. | Tumori | 2023 |
| 38037739 | Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors. | | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 38086377 | Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. | Cell Rep Med | 2023 |
| 37795442 | ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. | Front Oncol | 2023 |
| 37702716 | Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37467457 | Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies. | JCO Precis Oncol | 2023 |
| 37146605 | Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. | Cancer Cell | 2023 |
| 36892847 | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 36952643 | Reply to S. Chakrabarti and A. Mahipal. | | 2023 |
| 37072398 | Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. | Nat Commun | 2023 |
| 37255363 | Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 37438589 | Practical recommendations for using ctDNA in clinical decision making. | | 2023 |
| 35133659 | Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions. | Cancer | 2022 |
| 36045271 | Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. | Breast Cancer Res Treat | 2022 |
| 36092362 | Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an <i>H</i> <i>.</i> <i>pylori</i> immunostimulatory bacterial transgene. | Mol Ther Methods Clin Dev | 2022 |
| 35623341 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. | Cancer Cell | 2022 |
| 35931884 | Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. | Nat Cancer | 2022 |
| 35734391 | Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. | NAR Cancer | 2022 |
| 35788722 | Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. | Nat Cancer | 2022 |
| 35721584 | Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. | JCO Precision Oncology | 2022 |
| 35401896 | Local Recurrence of Invasive Secretory Breast Carcinoma in a Gravid Patient Post-Mastectomy. | Radiology Case Reports | 2022 |
| 36400018 | Evaluation of cell-free DNA approaches for multi-cancer early detection. | Cancer Cell | 2022 |
| 36612153 | Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma. | Cancers (Basel) | 2022 |
| 36457510 | Automated lesion detection of breast cancer in [<sup>18</sup>F] FDG PET/CT using a novel AI-Based workflow. | Front Oncol | 2022 |
| 36456573 | Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. | NPJ Breast Cancer | 2022 |
| 34911739 | NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. | Cancer Immunol Res | 2022 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 34529000 | Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 33968403 | Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. | Clinical and Translational Immunology | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 34117261 | Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. | npj Breast Cancer | 2021 |
| 34168046 | RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. | Clin Cancer Res | 2021 |
| 34111149 | Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer. | PLoS ONE | 2021 |
| 34108182 | Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. | Clin Cancer Res | 2021 |
| 33999652 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2021 |
| 33674749 | Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance. | Oncogene | 2021 |
| 33558712 | Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects. | British Journal of Cancer | 2021 |
| 34143979 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | Cancer Cell | 2021 |
| 34088722 | Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. | Clin Cancer Res | 2021 |
| 34298717 | The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. | Cancers (Basel) | 2021 |
| 33152119 | STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial. | International Journal of Cancer | 2021 |
| 33389409 | A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. | Breast Cancer Res Treat | 2021 |
| 34703985 | <i>BRAF</i> V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance). | Mayo Clin Proc Innov Qual Outcomes | 2021 |
| 32701140 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 32070401 | TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. | Breast Cancer Res | 2020 |
| 32233063 | Liquid Biopsy: Emergence of an Alternative Cancer Detection Method. | Clinical and Translational Science | 2020 |